Covid-19 Associated Mucormycosis (Cam) in Kashan, Iran: Clinical Presentations, Risk Factors, Management, and Outcomes Publisher Pubmed



Erami M¹ ; Raiesi O^{2, 3} ; Momenheravi M⁴ ; Mirhendi H⁵ ; Aboutalebian S⁵ ; Getso MI^{1, 6} ; Matini AH⁷ ; Ahsaniarani AH⁸ ; Ganjizadeh M⁹ ; Hassani Josheghani H⁹ ; Amiri S¹⁰ ; Pakzad R^{11, 12} ; Hashemi SJ¹ Show Affiliations
Source: Infectious Diseases Published:2024

Abstract

Background: This study aimed to estimate the disease burden and describe the clinical presentation, risk factors, and outcome of CAM in a single centre in Iran. Methods: A case of mucormycosis was defined as one that had clinical and radiological features consistent with mucormycosis along with demonstration of the fungus in tissue via KOH mount/culture/histopathological and molecular examination. Results: We report 30 cases of COVID-19 associated mucormycosis (CAM). The results of this study showed the affected age group in the range of 40–79 years (median = 65.5; IQR = 5) with women (16/30, 53%) affected more than men (14/30, 47%). Among the fungi recovered, Rhizopus oryzae had the highest frequency (79%). Out of the 30 patients, 28 (93%) patients were diabetic with 24 (80%) patients having other co-morbidities. Headache followed by retro-orbital pain, proptosis/ptosis and rapid diminution of vision was a common sequence of symptoms reported by the majority of cases. Use of mechanical ventilation (58% vs. 6%, p = 0.003), O2 required (92% vs. 50%, p = 0.024), and development of renal dysfunction during hospital stay (17% vs. 0%, p = 0.041) was significantly higher in non-survivors than survivors. Temperature (C°), PR (pulse rate), mean levels of serum creatinine, BUN, troponin, and neutrophils were significantly higher in non-survivors (p < 0.05). Besides, Albumin and PO2 were also significantly higher in survivors than non-survivors. Conclusion: Despite medical and surgical treatment, the mortality rate among CAM patients is still high. Thus, concerted efforts of revamping surveillance, diagnosis and management, along with public awareness and patient education, are the requisites for managing COVID-19 and mucormycosis. © 2023 Society for Scandinavian Journal of Infectious Diseases.